<DOC>
	<DOC>NCT00586157</DOC>
	<brief_summary>The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.</brief_summary>
	<brief_title>Study of Medication Patch to Treat Children Ages 6-12 With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male and female outpatients 6 to 12 years of age. Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSMIV, as manifested in clinical evaluation and confirmed by structured interview. Participation in structured morning routine (e.g. school, camp, or other organized activities). Mental retardation (IQ &lt;75). Subjects with a medical condition, or treatment that will either jeopardize subject safety or affect the scientific merit of the study. Subjects with moderate to severe dermatological atopy. Subjects with known structural cardiac abnormalities. Organic brain disorders. Seizure Disorder. Subjects with Tourette's syndrome, or a history of psychosis or bipolar disorder. Subjects with current comorbid psychopathology that in the investigator's opinion will warrant immediate treatment or will interfere with the safe execution of the protocol (i.e. Anxiety or Major Depressive Disorder rated as moderate on CGI). Subjects with a history of intolerable adverse effects or nonresponse to methylphenidate. Pregnant or nursing females.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Daytrana</keyword>
	<keyword>MTS Patch</keyword>
	<keyword>Methylphenidate Transdermal System</keyword>
</DOC>